focal segmental

AC1903 is a specific inhibitor of TRPC5 channel, and has been shown to suppress severe proteinuria and prevent podocyte loss.

Antroquinonol ((+)-Antroquinonol) is a natural product and an activator of the Nrf2 signaling pathway, exhibiting anti-inflammatory, antioxidant, and anticancer activities. The compound is cell-permeable and can be used in research on non-small cell lung cancer and colon cancer. Antroquinonol has also shown potential in inhibiting inflammation and fibrosis in models of focal segmental glomerulosclerosis.

APOL1-IN-1 is a potent inhibitor of apolipoprotein L1 (APOL1) that can be used to study the pathogenesis of focal segmental glomerulosclerosis (FSGS) and nondiabetic kidney disease (NDKD), facilitating research into these diseases.

Ilacirnon sodium is a potent CCR2 antagonist that may be useful in the treatment of renal diseases including Focal Segmental Glomerulosclerosis and Diabetic Nephropathy.

Fresolimumab (GC1008) is a specific human anti-transforming growth factor β monoclonal antibody that binds to the active forms of human TGFβ1, TGFβ2, and TGFβ3 and can be used to study focal segmental glomerulosclerosis and cancer in adults.

BMS-986090 is a humanized monoclonal antibody antagonist targeting CD40. It shows potential for use in studying autoimmune diseases, such as systemic lupus erythematosus (SLE) and focal segmental glomerulosclerosis (FSGS).